Guggenheim Reiterates “Buy” Rating for AbbVie (NYSE:ABBV)
Guggenheim reissued their buy rating on shares of AbbVie (NYSE:ABBV – Free Report) in a research note published on Thursday morning,Benzinga reports. The firm currently has a $214.00 price target on the stock. Other equities research analysts also recently issued research reports about the stock. The Goldman Sachs Group reiterated a “neutral” rating and issued […]
Guggenheim reissued their buy rating on shares of AbbVie (NYSE:ABBV – Free Report) in a research note published on Thursday morning,Benzinga reports. The firm currently has a $214.00 price target on the stock. Other equities research analysts also recently issued research reports about the stock. The Goldman Sachs Group reiterated a “neutral” rating and issued […]